Why Is Moderna (MRNA) Stock Rocketing Higher Today
Anthony Lee
Thu, August 20, 2026 at 3:04 AM GMT+5:30
1 min read
- MRNA
+176.97%
What Happened?
Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 144% in the afternoon session after its personalized mRNA cancer vaccine, developed with Merck, met key goals in a late-stage trial.
The company noted in a press release that the treatment, Intismeran, reduced the risk of melanoma recurrence and prevented tumors from spreading when combined with Merck’s Keytruda, compared with Keytruda alone. In addition, the readout marked the first successful late-stage trial for an mRNA cancer vaccine, validating Moderna’s platform beyond COVID-19. JPMorgan analysts told Reuters the vaccine’s launch is crucial to Moderna’s return to profitability
Is now the time to buy Moderna? Access our full analysis report here, it’s free
What Is The Market Telling Us
Moderna’s shares are extremely volatile and have had 49 moves greater than 5% over the last year. But moves this big are rare even for Moderna and indicate this news significantly impacted the market’s perception of the business
Moderna is up 409% since the beginning of the year, and at $157.08 per share, it has set a new 52-week high. Despite the year-to-date gain, investors who bought $1,000 worth of Moderna’s shares 5 years ago would now be looking at only $418.28
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE
